SuanFarma-Header SuanFarma-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): PulmoStem

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: PulmoStem

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $6.9 million Upfront Cash: Undisclosed

            Deal Type: Public Offering July 12, 2021

            Details:

            The funds will now be deployed to advance the company's preclinical portfolio of cell therapy candidates based on mesenchymal stem cells (MSC) from amniotic fluid. Lead candidate PulmoStem™, a first-in-class treatment for pulmonary disease is scheduled to enter the clinic.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): RES030-085

            Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RES030-085

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $0.3 million Upfront Cash: Undisclosed

            Deal Type: Agreement May 20, 2021

            Details:

            The agreement focuses on the development of an inhalation formulation as well as an inhalation product for phase I studies for Respiratorius drug candidate RES030-085 within the RESP9000 project for the treatment of COPD and severe asthma.